JW Pharmaceutical Corporation (KRX:001060)
South Korea flag South Korea · Delayed Price · Currency is KRW
26,350
+250 (0.96%)
Jun 10, 2026, 3:30 PM KST

JW Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
71,52461,51165,04037,00631,892-967.85
Depreciation & Amortization
19,09218,74819,10122,57516,83616,112
Loss (Gain) From Sale of Assets
31.7346.76-464.911,088-3.281,048
Asset Writedown & Restructuring Costs
--1,476-4,821-
Loss (Gain) From Sale of Investments
-2,474-1,578-790.9-2,8308,5151,820
Loss (Gain) on Equity Investments
-2,193-2,259-1,387-621.061,3491,149
Provision & Write-off of Bad Debts
-2,239-3,216-6,081-3,6448,43712,073
Other Operating Activities
17,58114,72311,78253,846-8,91332,946
Change in Accounts Receivable
13,33924,02229,965-4,734-4,312-41,566
Change in Inventory
5,320340-8,7758,917-11,541-2,655
Change in Accounts Payable
-11,953-3,512-14,527-9,53631,6523,730
Change in Unearned Revenue
22.01---153.66-53.5-
Change in Other Net Operating Assets
-22,735-12,429-15,946-14,756-21,915-5,564
Operating Cash Flow
85,31696,39679,39287,15756,76418,124
Operating Cash Flow Growth
17.85%21.42%-8.91%53.54%213.20%-71.26%
Capital Expenditures
-10,731-11,772-8,313-27,286-9,919-7,467
Sale of Property, Plant & Equipment
45.4545.4546.424.976.2663,446
Cash Acquisitions
---138.7-12,005-40.88-
Divestitures
-----384.96
Sale (Purchase) of Intangibles
-23,533-24,348-17,734-13,419-2,433-5,435
Investment in Securities
3,32634,05531,7258,260-26,3441,078
Other Investing Activities
-780.84-4,078358.72-6,355267.37-44,541
Investing Cash Flow
-52,673-7,19814,085-63,780-18,919-22,869
Short-Term Debt Issued
-56,098104,737227,876110,89675,323
Long-Term Debt Issued
--25,10260,16629,58560,296
Total Debt Issued
56,09856,098129,839288,042140,481135,619
Short-Term Debt Repaid
--80,498-171,805-316,108-177,004-84,408
Long-Term Debt Repaid
--14,767-47,809-4,051-2,795-16,845
Total Debt Repaid
-83,805-95,265-219,613-320,159-179,799-101,254
Net Debt Issued (Repaid)
-27,707-39,167-89,774-32,117-39,31834,365
Issuance of Common Stock
----10,000398.47
Repurchase of Common Stock
-4,787-9,540-750.42-260.88-281.6-412.29
Common Dividends Paid
-11,068-11,068-9,665-8,814-7,352-7,149
Other Financing Activities
---0-5444-0
Financing Cash Flow
-43,563-59,776-100,190-41,245-36,90727,202
Foreign Exchange Rate Adjustments
-350.25-619.741,234-120.69-406.38458.72
Net Cash Flow
-11,27028,803-5,479-17,989531.4522,915
Free Cash Flow
74,58584,62571,07959,87146,84510,657
Free Cash Flow Growth
20.55%19.06%18.72%27.81%339.56%-78.97%
Free Cash Flow Margin
9.44%10.91%9.88%8.00%6.84%1.76%
Free Cash Flow Per Share
3303.133734.592889.492515.252016.97459.20
Cash Interest Paid
2,2972,9448,13611,1199,0357,567
Cash Income Tax Paid
30,53029,44416,58713,33531,621863.42
Levered Free Cash Flow
61,05283,59241,86423,38174,265-6,672
Unlevered Free Cash Flow
63,81786,35748,13531,23280,132-2,087
Change in Working Capital
-16,0078,420-9,283-20,263-6,170-46,056